Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2342 - Characteristics and Prognostic Impact of Advanced Non-Small-Cell Lung Cancer Patients Who Were Ineligible for Clinical Trials


09 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Non-Small Cell Lung Cancer


Hayato Kawachi


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


H. Kawachi1, D. Fujimoto1, T. Morimoto2, M. Ito1, S. Teraoka1, Y. Sato1, K. Nagata1, A. Nakagawa1, K. Otsuka1, Y. Imai3, K. Tomii1

Author affiliations

  • 1 Respiratory Medicine, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 2 Clinical Epidemiology, Hyogo College of Medicine, 663-8501 - Nishinomiya/JP
  • 3 Clinical Pathology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP


Abstract 2342


The majority of non-small cell lung cancer (NSCLC) patients are ineligible for clinical trials. Nevertheless, very few studies report the profiles and treatment outcomes of such ineligible patients. Therefore, we investigated the characteristics, outcomes, and survival of advanced NSCLC patients who were ineligible for clinical trials.


We analyzed a retrospective cohort of 786 consecutive patients diagnosed with advanced NSCLC between January 2006 and December 2014. We reviewed the criteria in phase 3 clinical trials, and classified patients using the common first-line eligibility criteria for lung cancer.


Of the 786 patients, 469 (60%) were ineligible for clinical trials. The main reasons for ineligibility were brain metastasis (41%), a poor performance status (PS) (25%), and respiratory disease (24%). In all patients, ineligibility was identified as an independent predictor of overall survival (OS) (adjusted hazard ratio [HR] 0.78, 95% confidence interval [CI], 0.65–0.93, P = 0.008), even in patients with a good PS who received chemotherapy (HR 0.80, 95% CI, 0.65–0.99, P = 0.037). In subgroup analyses of ineligible patients, the survival varied depending on the reasons for their ineligibility. In particular, prior cancer history was not associated with a poor outcome, though this was a common reason for ineligibility (14.5%).


Most patients were ineligible for clinical trials and had shorter survival. The survival of ineligible patients varied depending on the reasons for their ineligibility. We should consider these results when applying clinical trial outcomes to real-world patients. More studies for ineligible patients are needed to improve real-world treatment.

Clinical trial identification

Legal entity responsible for the study

Daichi Fujimoto




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.